What does tesamorelin actually do?

It stimulates the pituitary to release the body's own growth hormone in a pulsatile way, which raises IGF-1 and preferentially reduces visceral (deep abdominal) fat. In the pivotal trial, visceral fat fell about 15 percent over 26 weeks versus an increase on placebo. The benefit reverses after stopping — visceral fat re-accumulates.

How is it dosed, and why daily if the half-life is so short?

It is a once-daily subcutaneous injection (approved doses run 1.28 to 2 mg depending on the formulation). Its plasma half-life is very short — roughly 10 to 40 minutes depending on the source — but the downstream growth-hormone and IGF-1 effect lasts much longer than the drug itself, which is why daily dosing works.

What are the main side effects?

Joint pain, injection-site reactions, swelling (edema) and muscle pain are most common. Critically, tesamorelin raises IGF-1, so IGF-1 must be monitored and the drug stopped if it stays elevated; it can also affect blood sugar and cause fluid retention. It is contraindicated in active malignancy, pituitary-axis disruption and pregnancy.

Is tesamorelin banned in sport?

Yes. As a GHRH analog it falls under WADA category S2.2 (growth-hormone-releasing factors) and is prohibited at all times, in and out of competition.

Tesamorelin: the GHRH analog, explained

Q: Is tesamorelin FDA-approved?

Yes — it is the only FDA-approved GHRH analog, sold as Egrifta (and the reformulations Egrifta SV and Egrifta WR). But it is approved only for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general fat loss, bodybuilding, anti-aging or in non-HIV populations; those uses are off-label. It was never approved in the EU — the marketing application was withdrawn in 2012.

Tesamorelin is a stabilized GHRH analog — and the only FDA-approved drug of its class, sold as Egrifta. It raises your own growth hormone to preferentially reduce visceral (deep abdominal) fat. But the approval is narrow: it's licensed only for HIV-associated lipodystrophy, and everything else is off-label. This page is the honest version: what it does, what the trials showed, the IGF-1 monitoring and side effects that matter, the short half-life, the reconstitution math, the anti-doping status, and how to track it. It is not dosing or sourcing advice.

By OptiPin Editorial·Last verified June 2026

Status — as of June 2026

FDA-approved as Egrifta — for one narrow indication. Tesamorelin is approved (2010) as Egrifta (and reformulations Egrifta SV / Egrifta WR) only for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general fat loss, bodybuilding, anti-aging or non-HIV use — those are off-label, and gray-market tesamorelin is unregulated. It was never approved in the EU (the application was withdrawn in 2012). It raises IGF-1 (requires monitoring) and is WADA-prohibited (S2.2, a GHRH analog). Nothing here is a recommendation about how to obtain or use it.

Class

GHRH analog

Target

GHRH-R → GH / IGF-1

Half-life

~10–40 min

Status

Approved (Egrifta) · narrow

TL;DR

• Tesamorelin is a stabilized GHRH analog — the only FDA-approved one (Egrifta) — that raises your own GH/IGF-1 to cut visceral fat.
• Approved only for HIV-lipodystrophy. General fat-loss / anti-aging use is off-label; never approved in the EU.
• It raises IGF-1 — monitor it. Side effects: joint pain, edema, glucose effects; benefit reverses on stopping.
• Once-daily SC; ~10–40 min half-life (effect outlasts it); WADA-banned (S2.2). This page is honest facts + math + tracking.

What it is

Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH) — a GHRH(1–44) analog with a trans-3-hexenoic acid group added to resist enzymatic breakdown. It's a GHRH-receptor agonist: it acts on the pituitary to stimulate release of your own (endogenous) growth hormone in a pulsatile, physiologic pattern, which in turn raises IGF-1. It's made by Theratechnologies. Importantly, it's the approved member of the GHRH-analog family — unlike the gray-market GHRH peptides CJC-1295 and sermorelin. (Note: ipamorelin is a different class — a ghrelin-receptor GHRP, not a GHRH analog.)

Approval & what the trials showed

Tesamorelin is FDA-approved as Egrifta (November 2010), with reformulations Egrifta SV and the newer Egrifta WR (2025), for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label is explicit that it's not for weight-loss management — the effect is on visceral fat specifically, and it's weight-neutral.

The pivotal evidence is the Phase 3 HIV-lipodystrophy program (Falutz et al., NEJM 2007, and LIPO-010/011): over 26 weeks, visceral adipose tissue fell ~15% on tesamorelin versus a ~5% increase on placebo. There's also genuine research interest in liver fat (NAFLD/NASH) in HIV (a 2019 Lancet HIV trial reduced hepatic fat), but that and any anti-aging/general-fat-loss use remain investigational and off-label. And the benefit is not durable: visceral fat re-accumulates after the drug is stopped.

The math

The approved Egrifta products are reconstituted by the patient per their instructions. The arithmetic on this page is for the gray-market lyophilized powder route — reconstituted with bacteriostatic water, dosed in milligrams — the same math the peptide reconstitution calculator does. Worked example, purely as arithmetic:

Vial label	10 mg lyophilized powder
Add	2 mL bacteriostatic water
Concentration	10 mg ÷ 2 mL = 5 mg/mL
Per 0.1 mL	0.5 mg — i.e. 10 units on a U-100 syringe = 0.5 mg
So a 2 mg dose would be	0.4 mL = 40 units

Concentration is just milligrams divided by millilitres, and units are just hundredths of a millilitre on a U-100 insulin syringe. The reconstitution calculator converts vial size + water + target into exact syringe units. The milligrams above are illustrative arithmetic, not a recommended dose — the approved doses are 1.28–2 mg daily depending on the formulation; off-label use is commonly reported around 1–2 mg/day but no validated off-label dose exists.

Half-life & daily dosing

Tesamorelin's plasma half-life is very short — the current Egrifta WR label cites ~11 minutes, while older sources cite ~26–38 minutes, so call it roughly 10–40 minutes, source-dependent. It's dosed once daily anyway, because the downstream GH/IGF-1 effect lasts far longer than the drug — the peptide triggers a GH pulse and then clears, but the IGF-1 elevation persists. You can see how a short half-life behaves with daily dosing in the half-life visualizer.

IGF-1 monitoring, side effects & storage

The defining safety point: tesamorelin raises IGF-1, so the label requires monitoring IGF-1 and discontinuing if it stays elevated (sustained high IGF-1 is the GH-axis safety concern). Other documented effects:

Most common: joint pain (arthralgia), injection-site reactions, swelling (peripheral edema), muscle pain.
Glucose: can impair glucose tolerance / raise blood sugar — monitor, especially with diabetes risk.
Fluid retention: edema and, occasionally, carpal-tunnel-type symptoms.
Contraindicated in active malignancy, disruption of the hypothalamic-pituitary axis, and pregnancy.
Storage: approved Egrifta per its label; gray-market powder kept cold/dark, reconstituted in bacteriostatic water and refrigerated at 2–8°C, used within about four weeks. Gray-market purity is not guaranteed.

This is not a prescription, a dose, or a sourcing guide. Only the HIV-lipodystrophy indication is approved; tesamorelin raises IGF-1 (which must be monitored), affects glucose, and is contraindicated in active malignancy. It's banned in tested sport. We are not prescribers. Discuss any GH-axis compound with a qualified clinician.

Tracking tesamorelin in OptiPin

If you're tracking a GH-axis protocol, OptiPin treats it like any other entry — without endorsing off-label use:

Daily dose log + reminders — record the once-daily injection and get reminded on the due day, with site rotation.
IGF-1 & glucose tracking — log bloodwork (IGF-1, fasting glucose/HbA1c) over your dose timeline — IGF-1 is the monitoring that actually matters here.
Waist & body metrics — log waist circumference and weight, since the effect is on visceral fat specifically (and weight-neutral).
OptiInsight analysis — OptiPin's AI reads the full record (doses, labs, measurements) and surfaces what moved with what.
Built-in reconstitution math — the same calculator covered above is one tap in the app.

Track it properly

Log doses, IGF-1 & waist in OptiPin

Daily reminders, IGF-1/glucose-over-dose charts, waist & weight tracking, vial runout warnings, built-in reconstitution math, and OptiInsight analysis — all on-device.

Download on the App Store

FAQ

Is tesamorelin FDA-approved?

Yes — the only approved GHRH analog (Egrifta / Egrifta SV / Egrifta WR), but only for visceral fat in HIV-associated lipodystrophy. General fat-loss/anti-aging use is off-label. Never approved in the EU (application withdrawn 2012).

What does it actually do?

Stimulates your own GH release → raises IGF-1 → preferentially reduces visceral (deep abdominal) fat (~15% over 26 weeks in trials). It's weight-neutral, and the benefit reverses after stopping.

Half-life and dosing?

Once-daily SC (approved 1.28–2 mg by formulation). Plasma half-life is short (~10–40 min, source-dependent), but the GH/IGF-1 effect lasts much longer, so daily dosing works.

Side effects?

Joint pain, injection-site reactions, edema, muscle pain. It raises IGF-1 (must be monitored), can affect blood sugar and cause fluid retention; contraindicated in active malignancy/pituitary disruption/pregnancy.

Is it banned in sport?

Yes — a GHRH analog under WADA S2.2 (growth-hormone-releasing factors), prohibited at all times.

Educational only, not medical advice. Only the HIV-lipodystrophy indication is FDA-approved. Tesamorelin raises IGF-1 (monitoring required), affects glucose, and is contraindicated in active malignancy. It's banned in tested sport. OptiPin does not recommend obtaining or using gray-market material. Discuss any GH-axis compound with a qualified clinician.

Sources

Ipamorelin + CJC-1295 · MK-677 · Peptides guide · Peptide reconstitution calculator · Half-life visualizer · Bloodwork